Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 21Oxaliplatin 17Leucovorin 17Bevacizumab 17Irinotecan 13Panitumumab 12Cetuximab 12IFL protocol 9Capecitabine 9pembrolizumab 7Radiotherapy 7Pemetrexed 5Gemcitabine 5labetuzumab 3conatumumab 3Cisplatin 3Carboplatin 3Albumin-Bound Paclitaxel 35,11-methenyltetrahydrohomofolate 3130-nm albumin-bound paclitaxel 3vatalanib 2trametinib 2spartalizumab 2pegfilgrastim 2ganitumab 2encorafenib 2dostarlimab 2Ramucirumab 2Paclitaxel 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Rectal Neoplasms × rilotumumab × Clear all
NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NantBioScience, Inc.

Phase 1/2 Completed
177 enrolled 31 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡